Novo Nordisk’s Teen Trial Win Offers a Glimmer as US Price War Bites

Novo Nordisk's oral semaglutide shows breakthrough in teens with type 2 diabetes, but US pricing squeeze and Eli Lilly competition have slashed shares 36% in a year.

The Danish drugmaker is fighting on two fronts: a promising pipeline breakthrough that could unlock a new patient population, and a brutal pricing squeeze in its core US market that has already wiped more than a third off the share price over the past year. For investors, the question is whether the long-term growth story can outweigh the immediate pain.

A First-in-Class Opportunity in Paediatric Diabetes

Novo Nordisk has unveiled positive results from its PIONEER TEENS phase 3 study, testing oral semaglutide in adolescents with type 2 diabetes. After 26 weeks, patients taking the drug saw their blood sugar levels drop by 0.83 percentage points compared with the placebo group. The data, presented at the European Congress on Obesity, marks the first time an oral GLP-1 receptor agonist has shown efficacy in minors.

The significance is hard to overstate. Existing treatments for this age group have serious limitations — metformin loses effectiveness in roughly half of young patients, while insulin carries risks of hypoglycaemia and unwanted weight gain. Novo Nordisk plans to file for regulatory approval in both the US and Europe during the second half of 2026. If successful, it would become the first approved GLP-1 pill for adolescents, handing the company a clear head start over arch-rival Eli Lilly, which has no presence in this segment.

The addressable market is expanding rapidly. Forecasts project nearly 21 million adolescents worldwide will be living with type 2 diabetes by 2030. Novo Nordisk is also investing in artificial intelligence to accelerate drug development, having recently struck a partnership with OpenAI.

The US Pricing Squeeze

Yet for all the pipeline promise, the stock remains under severe pressure. The shares currently trade at €35.46, down roughly 21 percent since the start of the year and almost 36 percent over the past twelve months. The relative strength index stands at 25.7, deep in oversold territory.

The main culprit is the US market. The FDA recently approved Eli Lilly’s oral GLP-1 drug Foundayo, stripping Novo Nordisk of its exclusivity in the tablet-based weight-loss space. Political pressure is also mounting on both companies to cut prices and improve patient access to expensive obesity and diabetes therapies. Novo Nordisk plans to respond this spring by launching an oral version of Ozempic and higher-dose Wegovy variants in the US.

Medicaid cuts and new pricing agreements are adding further strain. The company faces a tough year ahead as it tries to defend margins while expanding its product portfolio.

A One-Off Boost in the Q1 Numbers

On May 6, Novo Nordisk will report first-quarter results, and the headline figures will look distorted. The company is releasing a US rebate provision worth around $4.2 billion, which will artificially inflate both reported revenue and operating profit. Management plans to present adjusted metrics that strip out this one-off effect, giving investors a clearer view of underlying operational growth. The earnings call is scheduled for 1 pm.

Diversification as a Defence

The oral semaglutide franchise represents Novo Nordisk’s best bet for reducing its dependence on the increasingly competitive GLP-1 market. Expanding into paediatric diabetes would open a new revenue stream at a time when pricing pressure in the core adult segment shows no sign of easing. The stock has clawed back some ground in the past month, rising around 14 percent to €35.27, but the broader downtrend reflects a market that is still weighing near-term headwinds against long-term potential. The 2026 filing date for the adolescent indication now stands as a critical milestone — one that could determine whether Novo Nordisk can navigate its way out of the current storm.